Navigation Links
Gene signature spells poor outcome

Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones. Two melanoma patients with cancers of the same invasion depth and appearance under the microscope can have completely different outcomes, says Rhoda Alani, M.D., associate professor of oncology, dermatology and molecular biology and genetics at Hopkins Kimmel Cancer Center.

Alani says the way genes turn their protein-manufacturing machinery on and off in each cancer may help create a signature that can be used to identify tumors that are more prone to kill. These so-called expression patterns can be different from one stage of cancer to the next.

Her research team charted the level of gene expression in melanoma cell lines. Three of the lines mimic the least aggressive type, which grows along the uppermost surface of the skin, called radial growth phase. Four of the cell lines are typical of so-called vertical growth phase cancers, which invade inner skin layers, and another three represent the most lethal form -metastatic melanomas.

Two vertical growth phase cell lines had gene expression patterns similar to radial growth cancers, indicating that these cells were less aggressive, according to the scientists. The remaining two vertical growth cell lines contained patterns in 18 genes that paralleled metastatic cancer cell lines, the most aggressive form. Alani and her colleagues believe that within this group of 18 genes is a signature for aggressive melanomas.

Many of the genes described in the Hopkins report, published online on July 4 in PLoS One, were previously identified as associated with aggressive cancers by scientists at Johns Hopkins and elsewhere, but Alani says her study brings them all together for melanoma and links them to an aggressive profile.

Alanis team is validating these results in human tissue samples and evaluating gene correlations with patient outcomes. Funding for the study was provided by the National Cancer Institute. With further study, the genes could be used in tests that predict a patients prognosis and as targets for tailored therapies, she says.

Contact: Vanessa Wasta
Johns Hopkins Medical Institutions

Related medicine news :

1. Predicting Breast Cancer Recurrence By Understanding Gene Signature
2. Signature Campaign: Striking doctors take to the streets
3. Attention! Spells of momentary blindness following visual disturbance
4. Uncontrolled Diabetes Spells Doom for Dental Implants
5. Lip Service : Indiscriminate Kissing Spells Doom
6. Medicare Bulk Billing Spells Ill Health For The Health System
7. Community Health Shake-up Spells Trouble for Nurses
8. Heat Spells Trouble in South Carolina
9. The DNA That Spells Double Risk of Heart Attack
10. The DNA That Spells Double Risk of Heart Attack
11. Antifever drug betters stroke outcome
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology: